search
Back to results

Endoscopic Submucosal Dissection vs Local Laparoscopic Surgical Resection (TAMIS/TEO) in Early Rectal Neoplasias (DSETAMIS2018)

Primary Purpose

Rectal Neoplasms

Status
Unknown status
Phase
Not Applicable
Locations
Spain
Study Type
Interventional
Intervention
ESD
TAMIS
TEO
Sponsored by
Dr. Alberto Herreros de Tejada Echanojáuregui
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Rectal Neoplasms focused on measuring Early Rectal Neoplasms, ESD, TAMIS, TEO, Recurrence, R0, Safety

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients older than 18 y/o
  • Non-pedunculated rectal lesions (sessile 0-Is or flat 0-II) greater than 20 mm in diameter.
  • The edges of the lesion should be more than 3 cm from the external anal margin and up to 14 cm from it.
  • Circumferential involvement <50%

Exclusion Criteria:

  • Patients who refuse to participate.
  • Diagnosis of inflammatory bowel disease with rectal involvement.
  • Pregnant.
  • Anorectal fibrosis due to previous anorectal surgery.
  • Lateral Spreading Lesions (LST classification) Granular Homogeneous type
  • Lesions greater than 50 mm when there is suspicion of advanced histology (Kudo Vi superficial pattern).
  • Rectal lesions of any size with high suspicion of deep submucosal invasion or locoregional lymph node involvement, either in the diagnostic colonoscopy (Kudo Vn pit pattern, NICE 3 pattern, Sano IIIB pattern) or by complementary imaging tests (rectal EUS/Pelvic MRI)
  • Existence of synchronous colorectal lesions that require other surgical treatment in any case.

Sites / Locations

  • Hospital Universitario Marqués de Valdecilla
  • Hospital Universitario HM Montepríncipe
  • Hospital Universitario Puerta de HierroRecruiting
  • Hospital QuironSalud Málaga
  • Complejo Hospitalario de Navarra
  • Hospital de Sant Joan Despí Moisès Broggi
  • Hospital General Universitario Gregorio Marañón
  • Hospital Universitario 12 de Octubre

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Endoscopic Treatment

Minimally Invasive Laparoscopic Local Surgical Treatment

Arm Description

Rectal Endoscopic Submucosal Dissection

Transanal Minimally Invasive Surgery (TAMIS) or Transanal Endoscopic Operation (TEO)

Outcomes

Primary Outcome Measures

local recurrence rate
presence of remaining neoplastic tissue in resection site

Secondary Outcome Measures

En-bloq resection rate
Single piece of resection specimen
R0 resection rate
Free margin of neoplastic tissue both laterally and deep
Time per procedure
The length of the procedure expressed in minutes
Length of hospital stay
Days of hospital stay
Early complications rate
Registration of any deviations on the normal postoperative period in the first 24 hours
Delayed complications rate
Registration of any deviations on the normal postoperative period after the first 24 hours and up to 30 days after the procedure
Morbidity
Changes in patients' quality of life using validated scores (both, specific and non-specific)
Cost-effectiveness analyses (QALY)
Cost-effectiveness analyses usin QALYs
Short-term local recurrence rate
Presence of remaining neoplastic tissue in resection site

Full Information

First Posted
May 16, 2019
Last Updated
September 15, 2020
Sponsor
Dr. Alberto Herreros de Tejada Echanojáuregui
Collaborators
Spanish Society of Digestive Endoscopy
search

1. Study Identification

Unique Protocol Identification Number
NCT03959839
Brief Title
Endoscopic Submucosal Dissection vs Local Laparoscopic Surgical Resection (TAMIS/TEO) in Early Rectal Neoplasias
Acronym
DSETAMIS2018
Official Title
Endoscopic Submucosal Dissection Versus Local Laparoscopic Surgical Resection (Transanal Minimally Invasive Surgery [TAMIS] / Transanal Endoscopic Operation [TEO]) In Early Rectal Neoplasias. Multicentric and Randomized Clinical Trial
Study Type
Interventional

2. Study Status

Record Verification Date
September 2020
Overall Recruitment Status
Unknown status
Study Start Date
April 1, 2019 (Actual)
Primary Completion Date
April 1, 2021 (Anticipated)
Study Completion Date
April 1, 2022 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Dr. Alberto Herreros de Tejada Echanojáuregui
Collaborators
Spanish Society of Digestive Endoscopy

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
A multicenter non-inferiority randomized clinical trial to compare Endoscopic treatment (ESD) and Minimally Invasive Laparoscopic Local Surgical Treatment (TAMIS or TEO) for early rectal neoplastic lesions (adenoma & T1CRC) Primary aim: To compare the long-term local recurrence rate (12 months after the procedure) Secondary aims: Compare en-bloq resection rate, R0 resection, time per procedure, short-term recurrence rate, safety (rate of complications), morbidity and cost-effectiveness analyses.
Detailed Description
A multicenter non-inferiority randomized clinical trial is proposed to compare two types of treatment for early rectal neoplastic lesions. Study arms: Endoscopic treatment: Endoscopic Submucosal Dissection (ESD) Minimally invasive laparoscopic local surgical treatment: Transanal Minimally Invasive Surgery (TAMIS) or Transanal Endoscopic Operation (TEO). Aims: Primary aim: To compare the long-term local recurrence rate (12 months after the procedure) of rectal lesions after ESD vs Surgical treatment (TAMIS/TEO). Secondary aims: Both arms of the study are compared according to other efficacy-related variables (en-bloq resection rate, R0 resection, time per procedure, short-term recurrence rate [6 months]), safety (rate of complications), morbidity (comparing different specific indexes: Wexner index, EQ-5L-5D, etc) and cost-effectiveness analyses (QALY). Inclusion criteria: Patients older than 18 y/o Non-pedunculated rectal lesions (sessile 0-Is or flat 0-II) greater than 20 mm in diameter. The edges of the lesion should be more than 3 cm from the external anal margin and up to 14 cm from it. Circumferential involvement <50% Exclusion criteria: Patients who refuse to participate. Diagnosis of inflammatory bowel disease with rectal involvement. Pregnant. Anorectal fibrosis due to previous anorectal surgery. Lateral Spreading Lesions (LST classification) Granular Homogeneous type Lesions greater than 50 mm when there is suspicion of advanced histology (Kudo Vi superficial pattern). Rectal lesions of any size with high suspicion of deep submucosal invasion or locoregional lymph node involvement, either in the diagnostic colonoscopy (Kudo Vn crypt pattern, NICE 3 pattern, Sano IIIB pattern) or by complementary imaging tests (rectal EUS/Pelvic MRI) Existence of synchronous colorectal lesions that require other surgical treatment in any case. N-size estimation: Assuming a global rate of long-term local recurrence in rectal lesions treated by TAMIS/TEO or ESD of 2.5% (using the data available in the medical literature), considering a non-inferiority limit of 10%, power of 80% (Beta error 0.2, alpha error 0.05) and assuming a loss of patients during the follow-up around 10%, 34 patients per group are required. Follow-up and Information collect: The follow-up will be of 1 year from the date of the intervention and the visits in which the information to be analyzed will be collected are adjusted to the usual clinical practice. The data would be registered using the on-line database system for medical research RedCap. Other information: The entire protocol of this study has been approved by de Ethical Committee on Clinical Research of the Puerta de Hierro University Hospital. The study counts with a Civil Responsibility Insurance policy.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Rectal Neoplasms
Keywords
Early Rectal Neoplasms, ESD, TAMIS, TEO, Recurrence, R0, Safety

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
68 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Endoscopic Treatment
Arm Type
Experimental
Arm Description
Rectal Endoscopic Submucosal Dissection
Arm Title
Minimally Invasive Laparoscopic Local Surgical Treatment
Arm Type
Experimental
Arm Description
Transanal Minimally Invasive Surgery (TAMIS) or Transanal Endoscopic Operation (TEO)
Intervention Type
Procedure
Intervention Name(s)
ESD
Intervention Description
Rectal Endoscopic Submucosal Dissection
Intervention Type
Procedure
Intervention Name(s)
TAMIS
Intervention Description
Transanal Minimally Invasive Surgery
Intervention Type
Procedure
Intervention Name(s)
TEO
Intervention Description
Transanal Endoscopic Operation
Primary Outcome Measure Information:
Title
local recurrence rate
Description
presence of remaining neoplastic tissue in resection site
Time Frame
12 months
Secondary Outcome Measure Information:
Title
En-bloq resection rate
Description
Single piece of resection specimen
Time Frame
1 hour
Title
R0 resection rate
Description
Free margin of neoplastic tissue both laterally and deep
Time Frame
1 hour
Title
Time per procedure
Description
The length of the procedure expressed in minutes
Time Frame
1 hour
Title
Length of hospital stay
Description
Days of hospital stay
Time Frame
1 hour
Title
Early complications rate
Description
Registration of any deviations on the normal postoperative period in the first 24 hours
Time Frame
1 hour
Title
Delayed complications rate
Description
Registration of any deviations on the normal postoperative period after the first 24 hours and up to 30 days after the procedure
Time Frame
1 hour
Title
Morbidity
Description
Changes in patients' quality of life using validated scores (both, specific and non-specific)
Time Frame
12 months
Title
Cost-effectiveness analyses (QALY)
Description
Cost-effectiveness analyses usin QALYs
Time Frame
12 months
Title
Short-term local recurrence rate
Description
Presence of remaining neoplastic tissue in resection site
Time Frame
6 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients older than 18 y/o Non-pedunculated rectal lesions (sessile 0-Is or flat 0-II) greater than 20 mm in diameter. The edges of the lesion should be more than 3 cm from the external anal margin and up to 14 cm from it. Circumferential involvement <50% Exclusion Criteria: Patients who refuse to participate. Diagnosis of inflammatory bowel disease with rectal involvement. Pregnant. Anorectal fibrosis due to previous anorectal surgery. Lateral Spreading Lesions (LST classification) Granular Homogeneous type Lesions greater than 50 mm when there is suspicion of advanced histology (Kudo Vi superficial pattern). Rectal lesions of any size with high suspicion of deep submucosal invasion or locoregional lymph node involvement, either in the diagnostic colonoscopy (Kudo Vn pit pattern, NICE 3 pattern, Sano IIIB pattern) or by complementary imaging tests (rectal EUS/Pelvic MRI) Existence of synchronous colorectal lesions that require other surgical treatment in any case.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Diego de Frutos, MD
Phone
+34600826265
Email
diegodefrutos@gmail.com
First Name & Middle Initial & Last Name or Official Title & Degree
Alberto Herreros de Tejada, MD, PhD
Email
alberto.herreros@salud.madrid.org
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Eduardo Albéniz, MD, PhD
Organizational Affiliation
Complejo Hospitalario de Navarra
Official's Role
Study Director
Facility Information:
Facility Name
Hospital Universitario Marqués de Valdecilla
City
Santander
State/Province
Cantabria
Country
Spain
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Álvaro Terán
Facility Name
Hospital Universitario HM Montepríncipe
City
Boadilla Del Monte
State/Province
Madrid
Country
Spain
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Felipe Ramos
Facility Name
Hospital Universitario Puerta de Hierro
City
Majadahonda
State/Province
Madrid
ZIP/Postal Code
28222
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Diego de Frutos, MD
Phone
600826265
Email
diegodefrutos@gmail.com
Facility Name
Hospital QuironSalud Málaga
City
Málaga
State/Province
Malaga
Country
Spain
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Pedro Rosón, MD
Facility Name
Complejo Hospitalario de Navarra
City
Pamplona
State/Province
Navarra
ZIP/Postal Code
31008
Country
Spain
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Eduardo Albeniz, MD, PhD
Facility Name
Hospital de Sant Joan Despí Moisès Broggi
City
Barcelona
Country
Spain
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
David Barquero
Facility Name
Hospital General Universitario Gregorio Marañón
City
Madrid
Country
Spain
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Oscar Nogales
Facility Name
Hospital Universitario 12 de Octubre
City
Madrid
Country
Spain
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jose Carlos Marín

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Endoscopic Submucosal Dissection vs Local Laparoscopic Surgical Resection (TAMIS/TEO) in Early Rectal Neoplasias

We'll reach out to this number within 24 hrs